Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
ALK tyrosine kinase inhibitor

Xalkori (crizotinib)

An approved treatment for ALK-Positive Lung Cancer.

FDA Approved (2011)by Pfizer
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2011

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Crizotinib wherever you encounter it, plus the key facts at a glance.

Generic name
Crizotinib
Brand name
Xalkori
Development code
PF-02341066
Drug class
ALK tyrosine kinase inhibitor
Manufacturer
Pfizer
How it's taken
Oral capsules or oral pellets, twice a day

Xalkori (crizotinib) is a capsule taken twice a day for adults with non-small cell lung cancer that has spread (metastatic).

  • It is for tumors that test ALK-positive or ROS1-positive on an FDA-approved test[1].
  • The label also covers children 1 year and older and young adults with ALK-positive anaplastic large cell lymphoma (ALCL), a lymph system cancer. Their lymphoma must have come back or not responded to treatment. It also covers adults and children 1 year and older with ALK-positive inflammatory myofibroblastic tumor (IMT), a rare soft tissue tumor.
  • The IMT must be one that cannot be removed by surgery, has come back or has not responded[1].
  • The label says its safety and effectiveness have not been established in older adults with ALCL[1].
  • Xalkori comes as 200mg and 250mg capsules and as oral pellets in 20mg, 50mg and 150mg shells.
  • The shells are opened and emptied into the mouth for children and for adults who cannot swallow capsules[1][6].
  • The FDA first approved Xalkori for ALK-positive lung cancer on August 26, 2011 under accelerated approval[2].
  • The PROFILE 1014 trial included people who had not had treatment for advanced disease.
  • In this trial, the cancer took a median 10.9 months to grow on crizotinib against 7.0 months on platinum chemotherapy[1].
Follow Xalkori by email

We'll email you when Xalkori's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Crizotinib fits

Xalkori (crizotinib) is a twice-daily ALK inhibitor approved for adults with metastatic ALK-positive or ROS1-positive non-small cell lung cancer found by an FDA-approved test. It also comes as oral pellets for people who cannot swallow capsules[1].

  • Alectinib (Alecensa), brigatinib (Alunbrig), lorlatinib (Lorbrena) and ceritinib (Zykadia) are also FDA approved for metastatic ALK-positive lung cancer[11][12][13][15].
  • Ensartinib (Ensacove) is approved for people who have not taken an ALK inhibitor[14].
  • Neladalkib (Nelkarmi) has accelerated approval for locally advanced or metastatic disease that was already treated. That earlier treatment must be either alectinib as the only ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy[16].
  • The ALEX, ALTA 1L, CROWN and eXALT3 trials each compared a newer ALK inhibitor with crizotinib in people who had not taken an ALK inhibitor.
  • The labels for alectinib, brigatinib, lorlatinib and ensartinib each report a longer time before the cancer grew on the newer drug[11][12][13][14].
  • Outside the labels, the Phase 3 ALTA-3 trial compared brigatinib with alectinib in 248 people whose cancer had grown on crizotinib. It found no significant difference in the time before the cancer grew.
  • By independent review, the median was 19.3 months on brigatinib and 19.2 months on alectinib[10].
  • Anyone curious about crizotinib can ask their oncologist how its trial results line up with the newer ALK inhibitors, and whether ROS1 or ALK testing changes which drugs fit them.

How Crizotinib works

In ALK-positive lung cancer, a piece of the ALK gene breaks off and joins another gene, such as one called EML4. The fused gene makes an ALK protein that stays switched on[1]. The label explains that this fusion protein drives cancer cells to grow and survive[1]. Crizotinib blocks the ALK protein, and it also blocks ROS1. This is the protein that drives ROS1-positive lung cancer, the other lung cancer on its label[1].

In laboratory tests it also blocked c-Met, another growth signal protein, and slowed tumors carrying EML4-ALK or NPM-ALK fusions in mice[1]. In laboratory tests, crizotinib also stopped the growth of ALCL cells carrying the NPM-ALK fusion at drug levels people reach[1].

Side effects and safety

What patients report

Xalkori has no boxed warning, and the label lists no contraindications[1]. The label's warnings are liver injury, lung inflammation, a heart rhythm change called QT prolongation, a slow heart rate and severe vision loss. It also warns of severe stomach and bowel side effects in children and young adults with ALCL or children with IMT, and of harm to an unborn baby[1].

Liver: Across 1,719 people treated for lung cancer, liver injury was fatal in 0.1%[1]. The liver enzyme ALT rose above 5 times the normal limit in 11% and AST in 6%. These rises usually came in the first 2 months, and 1.0% stopped Xalkori for good because of them[1]. Liver blood tests are checked every 2 weeks for the first 2 months, then monthly and as needed[1].

Lungs: Interstitial lung disease, also called pneumonitis, is swelling and scarring of lung tissue. It occurred in 2.9% of the 1,719 people, usually within 3 months of starting. It was grade 3 or 4 in 1% and fatal in 0.5%[1]. Xalkori is stopped for good if drug-related lung disease is found[1].

Heart rhythm: The QT interval on an ECG reached 500 milliseconds or more in 2.1% of 1,616 people. It rose by 60 milliseconds or more in 5% of 1,582 people[1]. The label says to avoid Xalkori in people born with long QT syndrome. It says to check ECGs and blood salts in people with heart failure, slow heart rhythms, salt imbalances or medicines that prolong the QT interval[1].

Slow heart rate: Bradycardia (a slow heart rate) occurred in 13% of the 1,719 people. Grade 3 fainting occurred in 2.4% against 0.6% on chemotherapy[1]. Heart rate and blood pressure are checked regularly. The label advises avoiding other medicines that slow the heart as far as possible. Examples are beta-blockers, non-dihydropyridine calcium channel blockers, clonidine and digoxin[1].

Vision: Vision changes occurred in 63% of the 1,719 people and usually began in the first week. The most common were blurred vision, flashes of light, floaters or trouble seeing. Of these, 95% were mild (grade 1)[1]. Loss of side vision with vision loss (grade 4) occurred in 0.2%, and damage to the optic nerve has been reported as a cause of vision loss[1].

The label recommends checking vision symptoms monthly for everyone taking Xalkori. For children and young adults with ALCL or children with IMT, it also recommends an eye exam within 1 month of starting and every 3 months. Xalkori is stopped for good for severe vision loss unless another cause is found[1].

Stomach and bowel in children: All 26 children and young adults with ALCL had stomach or bowel side effects, grade 3 in 27%. Among 14 children with IMT, 93% vomited and 86% had nausea[1]. The label recommends anti-nausea medicine before and during treatment for these groups[1].

Pregnancy: Xalkori can harm an unborn baby. The label calls for effective birth control during treatment and for 45 days after the last dose. It also says male patients with partners who could become pregnant should use condoms during treatment and for 90 days after[1]. Breastfeeding is not advised during treatment and for 45 days after, and Xalkori may reduce fertility in women and men[1].

Most common: In adults with lung cancer, the side effects seen in 25% or more were vision changes, nausea, diarrhea, vomiting, swelling and constipation. Others at that rate were raised liver enzymes, tiredness, less appetite, colds and other upper airway infections, dizziness and nerve tingling or numbness[1]. In PROFILE 1014, serious side effects occurred in 34% of people on Xalkori, and side effects were fatal in 2.3%. Side effects led 8% of people to stop Xalkori for good[1].

Kidneys and blood counts: Kidney cysts occurred in 3.0% of the 1,719 people. The kidney filtering rate (eGFR) fell from a median of 96 to 80 in the first 2 weeks. It then held steady from week 12 to week 104[1]. In PROFILE 1014, neutrophils (the infection-fighting white blood cells) dropped in 52% of people. The drop was grade 3 or 4 in 11%[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Crizotinib

For adults with lung cancer, the label dose is 250mg by mouth twice a day, with or without food[1]. Capsules are swallowed whole, not chewed, crushed or split[1]. Adults who cannot swallow capsules can take oral pellets instead, 250mg (2 shells of 50mg and 1 of 150mg) twice a day[1]. The pellet shells are not swallowed. Each shell is opened and the pellets are emptied straight into the mouth or onto a spoon or medicine cup.

The person then drinks enough water to swallow them all. The pellets are not chewed or crushed[1]. For children and young adults with ALCL and children with IMT, the dose is 280mg per square meter of body surface twice a day. A table in the label sets the capsule or pellet combination by body size[1].

Missed or vomited doses: A missed dose is taken unless the next dose is due within 6 hours, and no extra dose is taken after vomiting[1].

Lower doses: For side effects in adults, the doctor may pause Xalkori or lower the dose to 200mg twice a day and then 250mg once a day. Xalkori is stopped for good in adults who cannot tolerate 250mg once a day[1]. Lower starting doses are set for moderate or severe liver impairment and for severe kidney impairment not needing dialysis[1].

Tests during treatment: Liver tests every 2 weeks for the first 2 months then monthly, and complete blood counts weekly for the first month then at least monthly[1]. A pregnancy test is done before starting for anyone who could become pregnant[1].

Other medicines: The label says to avoid strong CYP3A inhibitors, which raise crizotinib levels. If one cannot be avoided, the label says to lower the Xalkori dose[1]. Grapefruit and grapefruit juice are avoided for the same reason, and strong CYP3A inducers are avoided because they lower crizotinib levels[1]. Crizotinib raises the levels of some medicines broken down by CYP3A, and the label also advises avoiding medicines that prolong the QT interval or slow the heart rate[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Xalkori

With private insurance, the drugmaker's copay card can lower what you pay for Xalkori. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. People on Medicare may still qualify for the drugmaker's free medicine program. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Xalkori (Crizotinib)
  • Copay help

    Pfizer Oncology Together Co-Pay Savings: eligible commercially insured patients may pay as little as $0 per month, with up to $10,600 per product in savings each year. Not for anyone enrolled in a state or federally funded program such as Medicare, Medicaid, TRICARE or VA health care.

    For: private insurance · source
  • Free medicine program

    Pfizer Patient Assistance Program: may provide prescribed Pfizer Oncology medicines free to eligible patients who are uninsured or have government insurance and cannot afford their out-of-pocket costs. People with Medicare are first helped to look for other funding such as Extra Help; uninsured people are first helped to check Medicaid. Commercially insured patients are not eligible.

    For: no insurance, Medicare, Medicaid · source
  • Insurance and case manager help

    Pfizer Oncology Together helps people understand insurance benefits, and find financial help. Call 1-877-744-5675, Monday to Friday, 8am to 8pm Eastern.

    For: private insurance, Medicare, Medicaid, no insurance · source

Good to know: The xalkori.com financial assistance page and the Pfizer Oncology Together financial assistance page both state the $0 per month and $10,600 per product yearly co-pay terms. The Terms and Conditions block on xalkori.com still prints an older Co-Pay One card ($10 per 30-day prescription, $25,000 a year, program expires 12/31/2017); the record uses the current $0 and $10,600 terms shown on both pages. Neither page names a bridge or quick-start supply for Xalkori. No income limits are published for the free medicine program.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for ALK-Positive Lung Cancer

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for ALK-Positive Lung Cancer →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

PROFILE 1014 (NCT01154140) was a randomized, open-label Phase 3 trial in 343 people with metastatic ALK-positive lung cancer. None of them had had treatment for advanced disease. It compared crizotinib with pemetrexed plus cisplatin or carboplatin chemotherapy[1][8]. Results judged by independent reviewers[1]:

  • Median time before the cancer grew or the person died (progression-free survival) was 10.9 months on crizotinib and 7.0 months on chemotherapy
  • Tumors shrank in 74% on crizotinib and 45% on chemotherapy
  • Overall survival showed no statistically significant difference, and 84% of people on chemotherapy later took crizotinib

PROFILE 1007 (NCT00932893) was a randomized Phase 3 trial in 347 people whose cancer had grown after 1 platinum chemotherapy, comparing crizotinib with pemetrexed or docetaxel[1]. Median progression-free survival was 7.7 months on crizotinib and 3.0 months on chemotherapy, and tumors shrank in 65% against 20%[1]. Median overall survival was 21.7 and 21.9 months, with 89% of people on chemotherapy later taking crizotinib[1].

Other labeled uses: In 50 adults with ROS1-positive lung cancer in PROFILE 1001 (NCT00585195), tumors shrank in 66%, and the median response lasted 18.3 months[1]. In the ADVL0912 study (NCT00939770), lymphoma shrank in 88% of 26 children and young adults with ALCL and tumors shrank in 86% of 14 children with IMT[1]. In 7 adults with IMT, 5 had a response[1].

Trials against newer ALK inhibitors: Crizotinib was the comparison drug in the ALEX trial of alectinib and the ALTA 1L trial of brigatinib. It was also the comparison drug in the CROWN trial of lorlatinib and the eXALT3 trial of ensartinib. Each trial was in people who had not taken an ALK inhibitor[11][12][13][14]. Each of those labels reports a longer time before the cancer grew on the newer drug than on crizotinib in its own trial[11][12][13][14]. The trials were run separately, and results from separate trials cannot be compared with each other.

Development history

Pfizer developed crizotinib under the code PF-02341066[9][2]. The FDA approved Xalkori on August 26, 2011 under accelerated approval, which required Pfizer to complete later Phase 3 trials to confirm the benefit[2]. On November 20, 2013 the FDA added the PROFILE 1007 results to the label and said they verified that Xalkori gives clinical benefit, which fulfilled the accelerated approval requirement[2].

The same letter notes an Orphan Drug designation for this use[2]. The FDA added ROS1-positive lung cancer on March 11, 2016[3]. ALK-positive ALCL in children and young adults came next, on January 14, 2021[4]. ALK-positive IMT followed on July 14, 2022[5][7]. Xalkori oral pellets were approved on September 7, 2023 for the same uses as the capsules[6][7].

Ask anything about Crizotinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore ALK-Positive Lung Cancer trials

Other ALK-Positive Lung Cancer treatments

Common questions about Crizotinib

▸What is Crizotinib (Xalkori)?

Xalkori (crizotinib) is a capsule taken twice a day for adults with non-small cell lung cancer that has spread (metastatic). It is for tumors that test ALK-positive or ROS1-positive on an FDA-approved test[1]. The label also covers children 1 year and older and young adults with ALK-positive anaplastic large cell lymphoma (ALCL), a lymph system cancer. Their lymphoma must have come back or not responded to treatment. It also covers adults and children 1 year and older with ALK-positive inflammatory myofibroblastic tumor (IMT), a rare soft tissue tumor. The IMT must be one that cannot be removed by surgery, has come back or has not responded[1]. The label says its safety and effectiveness have not been established in older adults with ALCL[1]. Xalkori comes as 200mg and 250mg capsules and as oral pellets in 20mg, 50mg and 150mg shells. The shells are opened and emptied into the mouth for children and for adults who cannot swallow capsules[1][6]. The FDA first approved Xalkori for ALK-positive lung cancer on August 26, 2011 under accelerated approval[2]. The PROFILE 1014 trial included people who had not had treatment for advanced disease. In this trial, the cancer took a median 10.9 months to grow on crizotinib against 7.0 months on platinum chemotherapy[1].

▸How does Crizotinib work?

In ALK-positive lung cancer, a piece of the ALK gene breaks off and joins another gene, such as one called EML4. The fused gene makes an ALK protein that stays switched on[1]. The label explains that this fusion protein drives cancer cells to grow and survive[1]. Crizotinib blocks the ALK protein, and it also blocks ROS1. This is the protein that drives ROS1-positive lung cancer, the other lung cancer on its label[1]. In laboratory tests it also blocked c-Met, another growth signal protein, and slowed tumors carrying EML4-ALK or NPM-ALK fusions in mice[1]. In laboratory tests, crizotinib also stopped the growth of ALCL cells carrying the NPM-ALK fusion at drug levels people reach[1].

▸What are the side effects of Crizotinib?

Xalkori has no boxed warning, and the label lists no contraindications[1]. The label's warnings are liver injury, lung inflammation, a heart rhythm change called QT prolongation, a slow heart rate and severe vision loss. It also warns of severe stomach and bowel side effects in children and young adults with ALCL or children with IMT, and of harm to an unborn baby[1].

Liver: Across 1,719 people treated for lung cancer, liver injury was fatal in 0.1%[1]. The liver enzyme ALT rose above 5 times the normal limit in 11% and AST in 6%. These rises usually came in the first 2 months, and 1.0% stopped Xalkori for good because of them[1]. Liver blood tests are checked every 2 weeks for the first 2 months, then monthly and as needed[1].

Lungs: Interstitial lung disease, also called pneumonitis, is swelling and scarring of lung tissue. It occurred in 2.9% of the 1,719 people, usually within 3 months of starting. It was grade 3 or 4 in 1% and fatal in 0.5%[1]. Xalkori is stopped for good if drug-related lung disease is found[1].

Heart rhythm: The QT interval on an ECG reached 500 milliseconds or more in 2.1% of 1,616 people. It rose by 60 milliseconds or more in 5% of 1,582 people[1]. The label says to avoid Xalkori in people born with long QT syndrome. It says to check ECGs and blood salts in people with heart failure, slow heart rhythms, salt imbalances or medicines that prolong the QT interval[1].

Slow heart rate: Bradycardia (a slow heart rate) occurred in 13% of the 1,719 people. Grade 3 fainting occurred in 2.4% against 0.6% on chemotherapy[1]. Heart rate and blood pressure are checked regularly. The label advises avoiding other medicines that slow the heart as far as possible. Examples are beta-blockers, non-dihydropyridine calcium channel blockers, clonidine and digoxin[1].

Vision: Vision changes occurred in 63% of the 1,719 people and usually began in the first week. The most common were blurred vision, flashes of light, floaters or trouble seeing. Of these, 95% were mild (grade 1)[1]. Loss of side vision with vision loss (grade 4) occurred in 0.2%, and damage to the optic nerve has been reported as a cause of vision loss[1]. The label recommends checking vision symptoms monthly for everyone taking Xalkori. For children and young adults with ALCL or children with IMT, it also recommends an eye exam within 1 month of starting and every 3 months. Xalkori is stopped for good for severe vision loss unless another cause is found[1].

Stomach and bowel in children: All 26 children and young adults with ALCL had stomach or bowel side effects, grade 3 in 27%. Among 14 children with IMT, 93% vomited and 86% had nausea[1]. The label recommends anti-nausea medicine before and during treatment for these groups[1].

Pregnancy: Xalkori can harm an unborn baby. The label calls for effective birth control during treatment and for 45 days after the last dose. It also says male patients with partners who could become pregnant should use condoms during treatment and for 90 days after[1]. Breastfeeding is not advised during treatment and for 45 days after, and Xalkori may reduce fertility in women and men[1].

Most common: In adults with lung cancer, the side effects seen in 25% or more were vision changes, nausea, diarrhea, vomiting, swelling and constipation. Others at that rate were raised liver enzymes, tiredness, less appetite, colds and other upper airway infections, dizziness and nerve tingling or numbness[1]. In PROFILE 1014, serious side effects occurred in 34% of people on Xalkori, and side effects were fatal in 2.3%. Side effects led 8% of people to stop Xalkori for good[1].

Kidneys and blood counts: Kidney cysts occurred in 3.0% of the 1,719 people. The kidney filtering rate (eGFR) fell from a median of 96 to 80 in the first 2 weeks. It then held steady from week 12 to week 104[1]. In PROFILE 1014, neutrophils (the infection-fighting white blood cells) dropped in 52% of people. The drop was grade 3 or 4 in 11%[1].

▸How is Crizotinib taken?

For adults with lung cancer, the label dose is 250mg by mouth twice a day, with or without food[1]. Capsules are swallowed whole, not chewed, crushed or split[1]. Adults who cannot swallow capsules can take oral pellets instead, 250mg (2 shells of 50mg and 1 of 150mg) twice a day[1]. The pellet shells are not swallowed. Each shell is opened and the pellets are emptied straight into the mouth or onto a spoon or medicine cup. The person then drinks enough water to swallow them all. The pellets are not chewed or crushed[1]. For children and young adults with ALCL and children with IMT, the dose is 280mg per square meter of body surface twice a day. A table in the label sets the capsule or pellet combination by body size[1].

Missed or vomited doses: A missed dose is taken unless the next dose is due within 6 hours, and no extra dose is taken after vomiting[1].

Lower doses: For side effects in adults, the doctor may pause Xalkori or lower the dose to 200mg twice a day and then 250mg once a day. Xalkori is stopped for good in adults who cannot tolerate 250mg once a day[1]. Lower starting doses are set for moderate or severe liver impairment and for severe kidney impairment not needing dialysis[1].

Tests during treatment: Liver tests every 2 weeks for the first 2 months then monthly, and complete blood counts weekly for the first month then at least monthly[1]. A pregnancy test is done before starting for anyone who could become pregnant[1].

Other medicines: The label says to avoid strong CYP3A inhibitors, which raise crizotinib levels. If one cannot be avoided, the label says to lower the Xalkori dose[1]. Grapefruit and grapefruit juice are avoided for the same reason, and strong CYP3A inducers are avoided because they lower crizotinib levels[1]. Crizotinib raises the levels of some medicines broken down by CYP3A, and the label also advises avoiding medicines that prolong the QT interval or slow the heart rate[1].

▸Is Crizotinib FDA approved?

Yes, Crizotinib (Xalkori) is FDA approved (2011) for the treatment of ALK-Positive Lung Cancer.

▸What is Xalkori used for?

Xalkori (crizotinib) is FDA approved for adults with metastatic non-small cell lung cancer that tests ALK-positive or ROS1-positive on an FDA-approved test.

Lymphoma: Xalkori is also approved for children 1 year and older and young adults with ALK-positive anaplastic large cell lymphoma that has come back or not responded to treatment.

IMT: Xalkori is approved for adults and children 1 year and older with ALK-positive inflammatory myofibroblastic tumor that cannot be removed by surgery, has come back or has not responded.

Forms: Xalkori comes as 200mg and 250mg capsules, and oral pellets in 20mg, 50mg and 150mg shells.

Safety: The label has no boxed warning.

More: ALK-positive lung cancer treatments compared

Source: Xalkori prescribing information, DailyMed, November 2026

▸What are the side effects of crizotinib?

Vision changes were the most common side effect, in 63% of 1,719 people treated for lung cancer. Most of these (95%) were mild.

Other common ones: Nausea, diarrhea, vomiting, swelling, constipation, raised liver enzymes, tiredness, less appetite, upper airway infections, dizziness and nerve tingling or numbness.

Warnings: Liver injury, lung inflammation, QT prolongation on an ECG, a slow heart rate and severe vision loss. Others are severe stomach and bowel side effects in children, and harm to an unborn baby.

Slow heart rate: Bradycardia occurred in 13% of the 1,719 people.

Monitoring: Liver tests every 2 weeks for the first 2 months then monthly, and blood counts weekly for the first month then at least monthly.

Source: Xalkori prescribing information, DailyMed, November 2026

▸How does crizotinib compare with alectinib and lorlatinib?

Head-to-head trials in people who had not taken an ALK inhibitor found a longer time before the cancer grew on alectinib and on lorlatinib than on crizotinib.

ALEX: Median progression-free survival was 25.7 months on alectinib and 10.4 months on crizotinib, as judged by independent reviewers.

CROWN: The lorlatinib median had not been reached when the label data were set, against 9.3 months on crizotinib.

Other trials: Brigatinib (ALTA 1L) and ensartinib (eXALT3) were also tested against crizotinib, and both labels report a longer time before the cancer grew.

Separate trials: Each result comes from its own trial, and results from separate trials cannot be compared with each other.

Newer drugs compared: The labels report their trials against crizotinib. Outside the labels, the ALTA-3 trial compared brigatinib with alectinib after crizotinib and found no significant difference in the time before the cancer grew.

Source: Alecensa prescribing information, DailyMed; Lorbrena prescribing information, DailyMed; ClinicalTrials.gov NCT03596866

▸Can Xalkori capsules be opened or crushed?

No. Xalkori capsules are swallowed whole and are not chewed, crushed or split.

Pellets: People who cannot swallow capsules can take Xalkori oral pellets, a separate form approved in 2023.

How pellets are taken: Each shell is opened and the pellets are emptied into the mouth or onto a spoon or medicine cup, then followed by water. The shells themselves are not swallowed, and the pellets are not chewed or crushed.

Adult pellet dose: The dose is 250mg, made of 2 shells of 50mg and 1 of 150mg, twice a day.

Source: Xalkori prescribing information, DailyMed, November 2026

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
  2. U.S. Food and Drug Administration · 2013-11-20. NDA 202570/S-6 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/202570Orig1s006ltr.pdf
  3. U.S. Food and Drug Administration · 2016-03-11. NDA 202570/S-016 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202570Orig1s016ltr.pdf
  4. U.S. Food and Drug Administration · 2021-01-14. NDA 202570/S-030 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/202570Orig1s030ltr.pdf
  5. U.S. Food and Drug Administration · 2022-07-14. NDA 202570/S-033 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/202570Orig1s033ltr.pdf
  6. U.S. Food and Drug Administration · 2023-09-07. NDA 217581 NDA APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217581Orig1s000ltr.pdf
  7. U.S. Food and Drug Administration · 2026-11-18. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570
  8. ClinicalTrials.gov · 2026-11-18. A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung. https://clinicaltrials.gov/study/NCT01154140
  9. ClinicalTrials.gov · 2026-11-18. An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene. https://clinicaltrials.gov/study/NCT00932893
  10. ClinicalTrials.gov · 2026-11-18. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03596866
  11. U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
  12. U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
  13. U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
  14. U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e
  15. U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e
  16. Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Xalkori by email

We'll email you when Xalkori's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site